Stay updated on Upadacitinib in RA: Safety & Efficacy Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib in RA: Safety & Efficacy Clinical Trial page.

Latest updates to the Upadacitinib in RA: Safety & Efficacy Clinical Trial page
- CheckyesterdayChange DetectedThe site footer’s revision identifier was updated from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the completed BALANCE-EXTEND upadacitinib study, including its design, outcomes, eligibility criteria, locations, and supporting documents.SummaryDifference100%

- Check22 days agoChange DetectedThe footer now displays site revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check29 days agoChange DetectedAn NIH-wide announcement banner directs visitors to transition updates and notes that NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check36 days agoChange DetectedThe ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2; the study record page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site revision label changed from v3.7.0 to v3.7.1. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Upadacitinib in RA: Safety & Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib in RA: Safety & Efficacy Clinical Trial page.